Targeting calcium cycling proteins in heart failure through gene transfer
- 1 January 2003
- journal article
- review article
- Published by Wiley in The Journal of Physiology
- Vol. 546 (1) , 49-61
- https://doi.org/10.1113/jphysiol.2002.026732
Abstract
Our understanding of cardiac excitation‐contraction coupling has improved significantly over the last 10 years. Furthermore, defects in the various steps of excitation‐contraction coupling that characterize cardiac dysfunction have been identified in human and experimental models of heart failure. The various abnormalities in ionic channels, transporters, kinases and various signalling pathways collectively contribute to the ‘failing phenotype.’ However, deciphering the causative changes continues to be a challenge. An important tool in dissecting the importance of the various changes in heart failure has been the use of cardiac gene transfer. To achieve effective cardiac gene transfer a number of obstacles remain, including appropriate vectors for gene delivery, appropriate delivery systems, and a better understanding of the biology of the disease. In this review, we will examine our current understanding of these various factors. Gene transfer provides not only a potential therapeutic modality but also an approach to identifying and validating molecular targets.Keywords
This publication has 106 references indexed in Scilit:
- Targeted Transduction Patterns in the Mouse Brain by Lentivirus Vectors Pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV Envelope ProteinsMolecular Therapy, 2002
- Effects of Na+/Ca2+-exchanger Overexpression on Excitation–contraction Coupling in Adult Rabbit Ventricular MyocytesJournal of Molecular and Cellular Cardiology, 2002
- Superior Tissue-Specific Expression from Tyrosinase and Prostate-Specific Antigen Promoters/Enhancers in Helper-Dependent Compared with First-Generation Adenoviral VectorsHuman Gene Therapy, 2002
- Rescue of Contractile Parameters and Myocyte Hypertrophy in Calsequestrin Overexpressing Myocardium by Phospholamban AblationPublished by Elsevier ,2001
- In vivo acceleration of heart relaxation performance by parvalbumin gene deliveryJournal of Clinical Investigation, 2001
- Maximal Inhibition of SERCA2 Ca2+ Affinity by Phospholamban in Transgenic Hearts Overexpressing a Non-phosphorylatable Form of PhospholambanPublished by Elsevier ,2000
- Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene deliveryJournal of Clinical Investigation, 1999
- Reduced Ca2+-Sensitivity of SERCA 2a in Failing Human Myocardium due to Reduced Serin-16 Phospholamban PhoshorylationJournal of Molecular and Cellular Cardiology, 1999
- Pentameric Assembly of Phospholamban Facilitates Inhibition of Cardiac Function in VivoPublished by Elsevier ,1998
- Relationship of abnormal intracellular calcium mobilisation to myocyte hypertrophy in human ventricular myocardiumCardiovascular Research, 1993